Last reviewed · How we verify
L-Asparagine (asparagine)
L-Asparagine (generic name: asparagine) is a drug. It is currently in unknown development.
L-Asparagine works by providing the body with a building block for protein synthesis.
L-Asparagine, also known as asparagine, is a naturally occurring amino acid. It is a small molecule modality that has been studied for its potential therapeutic effects. However, there is limited information available on its commercial status, approved indications, and safety profile. Further research is needed to fully understand its mechanism of action and potential applications. As a result, it is not currently recognized as a commercially available pharmaceutical agent.
At a glance
| Generic name | asparagine |
|---|---|
| Target | Amino acid transporter |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Think of L-Asparagine like a Lego brick. When your body needs to build new proteins, it uses amino acids like L-Asparagine to create the necessary building blocks. This process is essential for growth, repair, and maintenance of tissues throughout the body.
Approved indications
Common side effects
Key clinical trials
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (PHASE3)
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE3)
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (PHASE3)
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (PHASE3)
- Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) (NA)
- Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE3)
- QUILT-3.006 for Recurrent Medullary Thyroid Cancer (PHASE2)
- Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Asparagine CI brief — competitive landscape report
- L-Asparagine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about L-Asparagine
What is L-Asparagine?
How does L-Asparagine work?
What is the generic name of L-Asparagine?
What development phase is L-Asparagine in?
What does L-Asparagine target?
Related
- Target: All drugs targeting Amino acid transporter
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing